|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 5-ASA in ulcerative colitis:Improving treatment compliance显示文摘5-aminosalicylic acid(5-ASA)compounds are a highly effective treatment for ulcerative colitis(UC).While UC patient compliance in clinical studies is over 90%, only 40%of patients in every day life take their prescribed therapy.Adherence to medication has been emphasized recently by a Cochrane meta-analysis that has suggested that future trials of 5-ASA in UC should look at patient compliance rather than drug efficacy. Better compliance can be obtained by reducing the number of tablets and times of administration.Given that the 5-ASA formulations have different delivery systems that split the active moiety in various regions of the intestine,it is particularly important that an adequate dose of the drug arrives at the inflamed part of the colon.5-ASA Multi matrix(MMx)is a novel,high strength(1.2 g),oral formulation designed for oncedaily dosing.It releases the active moiety throughout the colon.Different studies with this compound have shown that it is as effective as 5-ASA enema in the treatment of mild-to-moderate,left-sided UC,and is comparable to a pH-dependent,delayed release 5-ASA (Asacol ),even if given once daily.Recently,the effectiveness in the acute phase of UC has been confirmed also in maintenance.In conclusion,at present,5-ASA MMx seems theoretically the best agent for maintaining patient compliance,and consequently,treatment effectiveness. | Cosimo Prantera Marina Rizzi | 2009 | World Journal of Gastroenterology2009，15，35： | 3 |
| 2 | Use of antibiotics in the treatment of Crohn’s disease显示文摘Many data coming from animal models and clinical observations support an involvement of intestinal microbiota in the pathogenesis of Crohn's disease(CD). It is hypothesized in fact,that the development of chronic intestinal inflammation is caused by an abnormal immune response to normal flora in genetically susceptible hosts.The involvement of bacteria in CD inflammation has provided the rationale for including antibiotics in the therapeutic armamentarium.However, randomized controlled trials have failed to demonstrate an efficacy of these drugs in patients with active uncomplicated CD,even if a subgroup of patients with colonic location seems to get benefit from antibiotics. Nitroimidazole compounds have been shown to be efficacious in decreasing CD recurrence rates in operated patients,and the use of metronidazole and ciprofloxacin is recommended in perianal disease.However,the appearance of systemic side effects limits antibiotic long-term employment necessary for treating a chronic relapsing disease.Rifaximin,characterized by an excellent safety profile,has provided promising results in inducing remission of CD. | Maria Lia Scribano Cosimo Prantera | 2013 | World Journal of Gastroenterology2013，19，5： | 2 |
| 3 | Antibiotics and probiotics in in- flammatory bowel disease :why,when, and how 显示文摘 | Prantera C Scribano ML | 2009 | Curr Opin Gastroenterol2009，，： | 1 |
| 4 | Mycobacteria and Crohn's disease: the endless story显示文摘 | Prantera C | 2007 | Dig Liver Dis2007，39，5： | 1 |
| 5 | Stress and exacerbation in ulcerative colitis: a prospective study of patients enrolled in remission显示文摘 | Susan Levenstein Cosimo Prantera Vilma Varvo Maria Lia Scribano Arnaldo Andreoli Carlo Luzi Massimo Arcà Eva Berto Giustina Milite Adriana Marcheggiano | 2000 | The American Journal of Gastroenterology2000，，： | 1 |
| 6 | Stress and exacerbation in ulcerative colitis : a prospective study of patients enrolled in remission 显示文摘 | Levenstein S Prantera C Varvo V | 2000 | Am J Gastroentere12000，95，： | 1 |
| 7 | Eosinophilic gastroenteritis in a young man显示文摘 | Famularo G Prantera C Nunnari J | | 0，，： | 1 |
| 8 | Antibiotics and inflammatory boweldiseases显示文摘 | Scribano ML Prantera C | 2013 | Dig Dis2013，31，34： | 1 |
| 9 | Probiotics for Crohn's disease: what have we learned? 显示文摘 | Prantera C | 2006 | Gut2006，55，： | 1 |
| 10 | Anti-tumour necrosis factor alpha (infliximab) in the treatment of severe ulcerative colitis:result of an open study on 13 patients显示文摘 | Kohn A Prantera C Pera A | 2002 | Dig Liver Dis2002，34，9： | 1 |
| 11 | Oral 5-aminosalicylic acid (Asacol) in the maintenance treatment of Crohn's disease 显示文摘 | Prantera C Pallone F Brunetti | 1992 | Gastroenterology1992，103，： | 1 |
| 12 | Psychological stress and disease activity in ulcerative colitis:a multidimensional cross-sectional-study显示文摘 | Levenstein S Prantera C Varvo V | 1994 | Am J Gastroenterol1994，89，8： | 1 |
| 13 | Medical treatment of moderate to severe Crohn's disease显示文摘 | Scribano M Prantera C | | 0，，2： | 1 |
| 14 | Probiotics and Crohn's disease显示文摘 | Prantera C Scribano ML | 2002 | Dig Liver Dis2002，34，2： | 1 |
| 15 | Degradation of gaso- line aromatic hydrocarbons by two N2-fixing soil bacteria显示文摘 | Prantera M T Dr0zdowicz A Gomes Leite S | 2002 | Biotech- nology Letters2002，24，1： | 1 |
| 16 | Ineffective-ness of probiotics in preventing recurrence afar curativeresection for Crohns'disease:a randomised controlled trial with LactobacillusGG显示文摘 | Prantera C SCRIBANO ML FALASCO G | 2002 | Gut2002，51，3： | 1 |
| 17 | Eosinophilic gastroenteritis in a young man显示文摘 | Famularo G Prantera C Nunnari J | | 0，，： | 1 |
| 18 | 5-aminoalicyclic acid enema versus oral sulphasazine in maintaining remission in ulcerative colitis显示文摘 | Andreoli A Spinena S Levenstein S Prantera C | 1994 | Italian Journal of Gastroenterology1994，26，3： | 1 |
| 19 | Antibiotics and probiotics ininflammatory bowel disease: why, when, and how显示文摘 | Prantera C Scribano ML | 2009 | Curr Opin Gastroenterol2009，25，： | 1 |
| 20 | Glucocorticosteroids in the treatment of inflammatory bowel disease and approaches to minimizing systemic activity显示文摘 | Prantera C Marconi S | 2013 | Therap Adv Gastroenterol2013，6，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员